All‑polyethylene versus hybrid titanium‑pegged glenoid for stemless anatomic total shoulder replacement
A Randomised, Multicentre, Prospective, Non-inferiority Clinical Study Analysing Outcomes of a Cemented Pegged Polyethylene Glenoid Component Versus a Hybrid Polyethylene and Trabecular Titanium Glenoid Component in Patients With Osteoarthritis Treated With an Anatomical SMR Stemless Shoulder Arthroplasty
This trial will test whether a cemented all‑polyethylene pegged glenoid or a hybrid trabecular titanium central‑peg glenoid gives better results for adults having a stemless anatomic total shoulder replacement for osteoarthritis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 94 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Spaarne Gasthuis Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Hoofddorp, North Holland) |
| Trial ID | NCT07520721 on ClinicalTrials.gov |
What this trial studies
Adults with symptomatic glenohumeral osteoarthritis who are candidates for primary stemless anatomic total shoulder arthroplasty are randomized 1:1 to receive either a cemented all‑polyethylene pegged glenoid or a hybrid trabecular titanium central‑peg glenoid. Randomization is multicentre, stratified with variable block sizes, and both patients and outcome assessors are blinded to the implant allocation. Eligible shoulders are limited to Walch types A1, A2 or B1 with retroversion ≤15° and adequate bone quality, and bilateral staged procedures are allowed if each meets criteria. Outcomes will compare implant performance and patient recovery following the allocated glenoid component during routine surgical care and follow-up.
Who should consider this trial
Good fit: Ideal candidates are adults with symptomatic shoulder osteoarthritis for over a year who need primary unilateral or staged bilateral stemless anatomic total shoulder arthroplasty, have good bone quality, and have a Walch A1/A2/B1 glenoid with retroversion ≤15°.
Not a fit: Patients with severe glenoid deformity (Walch B2/C), retroversion over 15°, poor bone quality, revision shoulder arthroplasty, or life expectancy under five years are unlikely to meet eligibility or benefit from this comparison.
Why it matters
Potential benefit: If successful, the hybrid central‑peg design could reduce glenoid loosening and improve implant longevity and shoulder function compared with the all‑polyethylene pegged option.
How similar studies have performed: Conventional cemented all‑polyethylene pegged glenoids have a long clinical track record while hybrid porous/metal central‑peg designs are newer with promising early to midterm results but not yet proven superior in long‑term randomized comparisons.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Both genders; 2. Age 18 years old; 3. Life expectancy over 5 years; 4. Patient has symptomatic shoulder osteoarthritis for more than 1 year and is submitted to previous conservative non-surgical treatments; 5. Patient is requiring primary unilateral or staged bilateral anatomic arthroplasty based on physical examination, medical history and X ray examination. (In cases where bilateral aTSA's are indicated, the patient will be included for the second aTSA again when the patient meets the inclusion criteria); 6. Good bone quality evaluated by the investigator on the basis of a risk factors analysis and the intraoperative estimation; 7. A diagnosis in the target shoulder of osteoarthritis; according to the classification of Walch, the glenoid should be a type A1, A2 or B1. Retroversion should not exceed 15 degrees. 8. Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent; 9. Patient has participated in the Informed Consent process and has signed the Informed Consent form previously approved by the Ethics Committee. Exclusion Criteria: 1. Patient requiring revision shoulder arthroplasty; 2. Osteoporosis with a history of non-traumatic fractures; 3. Steroid injections within the previous 6 months; 4. Contralateral shoulder replacement within the previous 3 months; 5. Meta-epiphyseal bony defect (including large cysts); 6. Significant proven or suspicious infection of the target shoulder or any serious infectious disease 7. Significant neurological or musculoskeletal disorders that may compromise functional recovery; 8. Known or suspicious hypersensitivity to the metal or other materials of the implant; 9. Unwillingness or inability (i.e. alcoholism, infirmity) to comply with rehabilitation and to return for follow-up visits and any psychiatric illness that would prevent comprehension of the details and nature of the study; 10. Any systemic disease which may affect outcome. 11. Active or metastatic neoplastic disease 12. Chemotherapy and/or radiotherapy within the last 6 months 13. Previous organ transplant 14. Participation in any clinical research study that may interfere with this study 15. A current or prior DSM-5 diagnosis of schizophrenia, delusional disorder, schizoaffective disorder, psychotic disorder or bipolar disorder. 16. Current substance use disorder (excluding nicotine/tabacco use disorder) or moderate or severe alcohol use disorder. 17. Imminent suicide risk. 18. Any other psychiatric condition that renders the individual unsuitable for the study according to the study physicians judgment
Where this trial is running
Hoofddorp, North Holland
- Spaarne Gasthuis — Hoofddorp, North Holland, Netherlands (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.